Category Archives: People

Vaso Corporation Appoints Shaun McMeans to Board of Directors

PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and proprietary medical products, today announced the appointment of Shaun McMeans to the Company’s Board of Directors, effective July 23, 2026. “We are pleased to […]

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, […]

Bread Financial Provides Performance Update for June 2026

COLUMBUS, Ohio, July 23, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated:   For […]

Bread Financial Reports Second Quarter 2026 Results

COLUMBUS, Ohio, July 23, 2026 (GLOBE NEWSWIRE) — Bread Financial® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced its second quarter 2026 financial results. All earnings-related materials are now available at the company’s investor relations website, here.  Bread Financial President and Chief Executive Officer Ralph Andretta and Chief Financial Officer Perry Beberman […]

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on […]

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) — Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, […]

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials iMDx […]

Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) — Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company’s […]

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for […]